GE HealthCare to buy Sofie Biosciences for $945 million in radiopharma push

By Vivian Lin · October 5, 2026, 11:47 PM · 3 mins read

GE HealthCare will pay $945 million to acquire Sofie Biosciences, aiming to ramp up its radiopharmaceutical output and secure US rights to a late-stage PET imaging agent for cancer.

GE HealthCare is putting $945 million on the table to buy Sofie Biosciences. The deal is all cash. It’s a direct move to grab a bigger share of the PET imaging drug market and get a firm hold on US cancer diagnostics.

At the center is FAPI-74. This is an experimental PET imaging agent now in late-stage trials. GE HealthCare already owns rights to FAPI-74 outside the US. With this buyout, it gets the US rights too. If FAPI-74 wins regulatory approval, GE HealthCare will be ready to compete hard in cancer detection. The company already sells Flyrcado, a PET imaging agent cleared by the US FDA for heart scans. Now it wants to break into oncology diagnostics.

Sofie Biosciences is described as a contract manufacturing organization (CMO) specializing in PET radiopharmaceuticals, providing critical last-mile supply infrastructure for F-18-based agents to hospitals and diagnostic centers across the US.

Deal structure and strategic context

Sofie Biosciences is owned by private equity firm Trilantic. The $945 million deal will fold Sofie into GE HealthCare’s pharmaceutical diagnostics business. Sofie brings a lineup of radioisotope products for PET scans and a network of manufacturing and distribution sites serving hospitals and imaging centers. After the deal closes, Sofie will keep supplying its current customers, including other radiopharma companies. The closing is expected in the first half of 2027.

An official company announcement says the deal still needs regulatory approval. Once done, Sofie will join GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment. The buyout will help GE HealthCare build a US distribution network for PET radiopharmaceuticals, especially F-18-based agents.

The radiopharma sector is seeing a wave of mergers. In August, Curium agreed to buy Lantheus in a deal worth up to $8 billion. Companies are racing to meet rising demand for radioactive drugs in cancer care. GE HealthCare has been expanding too. In March, it bought Intelerad, a Montreal medical imaging software firm, for $2.3 billion. That deal widened its reach in outpatient care and digital diagnostics.

After the acquisition, Sofie is expected to maintain its role as a contract manufacturer and continue supplying existing clients, including other radiopharmaceutical companies, rather than immediately shifting to exclusive internal production.

Quartz

Implications for radiopharmaceuticals and cancer imaging

GE HealthCare gets more than just manufacturing. It also picks up a late-stage oncology imaging asset that could change its US diagnostics pipeline. The plan is simple. GE HealthCare wants to add products that fit with its imaging systems and go deeper into the radiopharmaceuticals market. Deal activity and investment are both rising. As MedTech Dive reports, the US rights to FAPI-74—an F-18-based radiotracer now in Phase III trials for imaging many tumor types—are a key part of this deal. GE HealthCare already owns rights outside the US.

This is a bold step. GE HealthCare is betting that owning both manufacturing and late-stage imaging agents will drive future growth in cancer diagnostics. More deals are likely as the fight for radiopharma leadership heats up.

Topics:

Biotechnology Newsroom

Vivian Lin

Vivian Lin is Biotech Markets & Transactions Editor at GenoMethods, covering licensing agreements, M&A, biotech financing, company pipelines, strategic partnerships and cross-border transactions. Her reporting connects deal structure and company strategy with the scientific and clinical evidence underlying each biotechnology asset.